(Nanatinostat + Valganciclovir) is a small molecule commercialized by Viracta Therapeutics, with a leading Phase II program in Natural Killer Cell Lymphomas. According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of (Nanatinostat + Valganciclovir)s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for (Nanatinostat + Valganciclovir) is expected to reach an annual total of $275 mn by 2035 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
(Nanatinostat + Valganciclovir) Overview
Nana-Val is under development for the treatment for EBV-associated cancers including solid tumors like nasopharyngeal carcinoma, plasmablastic lymphoma, gastric carcinoma, leiomyosarcoma, sarcoma, angioimmunoblastic T-cell lymphoma, lymphoepithelioma, post-transplant lymphoproliferative disorder, cutaneous T cell lymphoma, diffuse large B cell lymphoma, systemic lupus erythematosus, and Hodgkin lymphoma. It is a small molecule administered orally. It is a combination of nanatinostat and valganciclovir. The drug is developed based on Esterase Sensitive Motif (ESM) technology. Nanatinostat acts by targeting HDAC and valganciclovir acts by targeting DNA polymerase.
It was also under development for the treatment of solid tumor, gastric cancer, nasopharyngeal cancer, colon cancer, natural killer cell lymphomas, peripheral T-cell lymphomas (PTCL), latent viral infections and relapsed/refractory multiple myeloma.
Viracta Therapeutics Overview
Viracta Therapeutics, develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company’s pipeline products include Nana-val for the treatment of Lymphoma and Solid Tumors; SSN-510 for the treatment of hematology and solid tumors. The company had partnered programs under development include TAK-580 (formerly MLN2480) and Vosaroxin for the treatment of various types of cancer. The company entered into partnership with Biogen, Takeda, DOT Therapeutics-1, Inc, Denovo Biopharma, LLC for the development of pipeline products. Viracta is headquartered in Cardiff, California, the US.
The operating loss of the company was US$50.7 million in FY2023, compared to an operating loss of US$50.6 million in FY2022. The net loss of the company was US$51.1 million in FY2023, compared to a net loss of US$49.2 million in FY2022.
For a complete picture of (Nanatinostat + Valganciclovir)s valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
